Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.

[1]  Walter Kolch,et al.  LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway , 2004, Journal of leukocyte biology.

[2]  Giulio Superti-Furga,et al.  A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.

[3]  Bertrand Séraphin,et al.  Recent developments in the analysis of protein complexes 1 , 2004, FEBS letters.

[4]  M. Hahne,et al.  The uncertain glory of APRIL , 2003, Cell Death and Differentiation.

[5]  J. Ferrara,et al.  The Pathophysiology of Acute Graft-versus-Host Disease , 2003, International journal of hematology.

[6]  Guixiu Shi,et al.  Death Decoy Receptor TR6/DcR3 Inhibits T Cell Chemotaxis In Vitro and In Vivo1 , 2003, The Journal of Immunology.

[7]  A. Anis,et al.  Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease , 2003, The Annals of pharmacotherapy.

[8]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[9]  J. Dahlerup,et al.  The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures , 2003 .

[10]  J. Gommerman,et al.  Lymphotoxin/LIGHT, lymphoid microenvironments and autoimmune disease , 2003, Nature Reviews Immunology.

[11]  O. Janssen,et al.  CD95 ligand - death factor and costimulatory molecule? , 2003, Cell Death and Differentiation.

[12]  P. Fink,et al.  Mutation in Fas Ligand Impairs Maturation of Thymocytes Bearing Moderate Affinity T Cell Receptors , 2003, The Journal of experimental medicine.

[13]  F. Rieux-Laucat,et al.  Cell-death signaling and human disease. , 2003, Current opinion in immunology.

[14]  Klaus Pfeffer,et al.  Biological functions of tumor necrosis factor cytokines and their receptors. , 2003, Cytokine & growth factor reviews.

[15]  M. Walsh,et al.  Biology of the TRANCE axis. , 2003, Cytokine & growth factor reviews.

[16]  I. Thesleff,et al.  Ectodysplasin signaling in development. , 2003, Cytokine & growth factor reviews.

[17]  R. Korngold,et al.  Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses , 2003 .

[18]  M. Mann,et al.  Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Green,et al.  Death fold domain interaction in apoptosis , 2003, Cell Death and Differentiation.

[20]  D. Newmeyer,et al.  Mitochondria Releasing Power for Life and Unleashing the Machineries of Death , 2003, Cell.

[21]  G. Kollias,et al.  Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Kanakaraj,et al.  A TNF Family Member LIGHT Transduces Costimulatory Signals into Human T Cells1 , 2002, The Journal of Immunology.

[23]  Guixiu Shi,et al.  Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. , 2002, Blood.

[24]  T. Uchiyama,et al.  Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. , 2002, Immunology letters.

[25]  A. Alcamí,et al.  Inhibition of Type 1 Cytokine–mediated Inflammation by a Soluble CD30 Homologue Encoded by Ectromelia (Mousepox) Virus , 2002, The Journal of experimental medicine.

[26]  George Kollias,et al.  Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. , 2002, Cytokine & growth factor reviews.

[27]  H. Schwarz,et al.  CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers , 2002, Journal of leukocyte biology.

[28]  Philip Rosenstiel,et al.  p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1 , 2002, The Journal of Immunology.

[29]  S. Deventer,et al.  Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease , 2002, Gut.

[30]  S. Chen‐Kiang,et al.  Mechanism of BLyS action in B cell immunity. , 2002, Cytokine & growth factor reviews.

[31]  M. Justice,et al.  Gene defect in ectodermal dysplasia implicates a death domain adapter in development , 2001, Nature.

[32]  M. Lewitzky,et al.  Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor1 , 2001, FEBS letters.

[33]  T. Whittall,et al.  CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. , 2001, Immunity.

[34]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[35]  S. V. Deventer,et al.  Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease , 2001 .

[36]  T. Honjo,et al.  Human genetic defects in class-switch recombination (hyper-IgM syndromes). , 2001, Current opinion in immunology.

[37]  E. Duda,et al.  Receptor-like properties of the 26 kDa transmembrane form of TNF. , 2001, European cytokine network.

[38]  S. Hsieh,et al.  Enhanced Proliferation and Increased IFN-γ Production in T Cells by Signal Transduced Through TNF-Related Apoptosis-Inducing Ligand1 , 2001, The Journal of Immunology.

[39]  K. Kaltoft,et al.  Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. , 2001, Cytokine.

[40]  M. Zvelebil,et al.  Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. , 2001, Journal of cell science.

[41]  K. Tanaka,et al.  Transmembrane TNF (pro‐TNF) is palmitoylated , 2001, FEBS letters.

[42]  A. Godzik,et al.  A Diverse Family of Proteins Containing Tumor Necrosis Factor Receptor-associated Factor Domains* , 2001, The Journal of Biological Chemistry.

[43]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[44]  Takahiko Horiuchi,et al.  Outside-to-Inside Signal Through the Membrane TNF-α Induces E-Selectin (CD62E) Expression on Activated Human CD4+ T Cells1 , 2001, The Journal of Immunology.

[45]  S. Hsieh,et al.  Enhanced Secretion of IFN-γ by Activated Th1 Cells Occurs Via Reverse Signaling Through TNF-Related Activation-Induced Cytokine1 , 2001, The Journal of Immunology.

[46]  P. Kostenuik,et al.  Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.

[47]  S. Ely,et al.  Engagement of CD153 (CD30 Ligand) by CD30+ T Cells Inhibits Class Switch DNA Recombination and Antibody Production in Human IgD+ IgM+ B Cells1 , 2000, The Journal of Immunology.

[48]  J K Frederiksen,et al.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.

[49]  R M Siegel,et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.

[50]  R. Andreesen,et al.  Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. , 2000, Biochemical and biophysical research communications.

[51]  Walter Kolch,et al.  Reverse Signaling Through Transmembrane TNF Confers Resistance to Lipopolysaccharide in Human Monocytes and Macrophages1 , 2000, The Journal of Immunology.

[52]  Don Foster,et al.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.

[53]  D. Harlan,et al.  Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis , 2000, The Journal of experimental medicine.

[54]  P. Fink,et al.  The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[56]  H. Schwarz,et al.  CD137 induces proliferation and endomitosis in monocytes. , 1999, Blood.

[57]  P. Lipsky,et al.  Expression, regulation, and function of B cell-expressed CD154 in germinal centers. , 1999, Journal of immunology.

[58]  A. Imura,et al.  Intracellular signaling of gp34, the OX40 ligand: induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40. , 1999, Journal of immunology.

[59]  R. V. van Lier,et al.  Aberrant expression and reverse signalling of CD70 on malignant B cells , 1999, British journal of haematology.

[60]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[61]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[62]  P. Scheurich,et al.  Continuous Autotropic Signaling by Membrane-expressed Tumor Necrosis Factor* , 1999, The Journal of Biological Chemistry.

[63]  H. Schwarz,et al.  Identification of CD137 as a potent monocyte survival factor , 1999, Journal of leukocyte biology.

[64]  David Wallach,et al.  A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signalling’ , 1999, The EMBO journal.

[65]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[66]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[67]  J. Desbarats,et al.  Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells , 1998, Nature Medicine.

[68]  J. Tschopp,et al.  APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth , 1998, The Journal of experimental medicine.

[69]  C. Thompson,et al.  Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. , 1998, Genes & development.

[70]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[71]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[72]  R. Andreesen,et al.  CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. , 1998, Journal of immunology.

[73]  S R Sprang,et al.  Modularity in the TNF-receptor family. , 1998, Trends in biochemical sciences.

[74]  Pamela J. Fink,et al.  Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand , 1998, The Journal of experimental medicine.

[75]  F. Lang,et al.  Evidence for a novel function of the CD40 ligand as a signalling molecule in T‐lymphocytes , 1997, FEBS letters.

[76]  Yuetsu Tanaka,et al.  Expression and function of OX40 ligand on human dendritic cells. , 1997, Journal of immunology.

[77]  F. Lang,et al.  The CD40 ligand directly activates T-lymphocytes via tyrosine phosphorylation dependent PKC activation. , 1997, Biochemical and biophysical research communications.

[78]  F. Lang,et al.  The CD40‐ligand stimulates T‐lymphocytes via the neutral sphingomyelinase : A novel function of the CD40‐ligand as signalling molecule , 1997, FEBS letters.

[79]  A. Weinberg,et al.  Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. , 1997, Blood.

[80]  D. Umetsu,et al.  Antigen-specific B cells preferentially induce CD4+ T cells to produce IL-4. , 1997, Journal of immunology.

[81]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[82]  T. Horiuchi,et al.  Membrane Tumor Necrosis Factor-α (TNF-α) Expressed on HTLV-I-Infected T Cells Mediates a Costimulatory Signal for B Cell Activation—Characterization of Membrane TNF-α , 1997 .

[83]  C. Smith,et al.  Reverse signaling via CD30 ligand. , 1996, Journal of immunology.

[84]  M. Hung,et al.  Human pro-tumor necrosis factor is a homotrimer. , 1996, Biochemistry.

[85]  D. Umetsu,et al.  Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis. , 1996, Journal of immunology.

[86]  W. Strober,et al.  The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response , 1996, The Journal of experimental medicine.

[87]  E Stuber,et al.  Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion , 1996, The Journal of experimental medicine.

[88]  D. Gray,et al.  CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.

[89]  R. Flavell,et al.  Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand , 1995, Nature.

[90]  M. Ueffing,et al.  Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. , 1995, Blood.

[91]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[92]  J. Tschopp,et al.  Interaction of peptides derived from the Fas ligand with the Fyn‐SH3 domain , 1995, FEBS letters.

[93]  J. Thompson,et al.  2 A crystal structure of an extracellular fragment of human CD40 ligand. , 1995, Structure.

[94]  G. Ledderose,et al.  Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha , 1995, Blood.

[95]  H. P. Fell,et al.  Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. , 1995, Immunity.

[96]  B. Scallon,et al.  Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[97]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[98]  C. Ferran,et al.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. , 1994, The Journal of clinical investigation.

[99]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[100]  R. Kriz,et al.  The cloning of CD70 and its identification as the ligand for CD27. , 1994, Journal of immunology.

[101]  L. Lanier,et al.  CD40 preferentially costimulates activation of CD4+ T lymphocytes. , 1994, Journal of immunology.

[102]  K. Pollok,et al.  4‐1BB T‐cell antigen binds to mature B cells and macrophages, and costimulates anti‐μ‐primed splenic B cells , 1994, European journal of immunology.

[103]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[104]  G. Aversa,et al.  The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation , 1993, The Journal of experimental medicine.

[105]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[106]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[107]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[108]  L. Gooding,et al.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.

[109]  W. Lehmacher,et al.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. , 1990, Blood.

[110]  T. Katagiri,et al.  A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse , 1990, The Journal of experimental medicine.

[111]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[112]  G. Crabtree.  Contingent genetic regulatory events in T lymphocyte activation. , 1989, Science.

[113]  L. Old.  Tumor necrosis factor. , 1988, Clinical bulletin.

[114]  Volker Herzog,et al.  Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes , 1988, International journal of cancer.

[115]  J. Pouysségur,et al.  Study of MAPK signaling using knockout mice. , 2004, Methods in molecular biology.

[116]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[117]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[118]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[119]  E. Am,et al.  An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application. , 2000 .

[120]  C. Ware,et al.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.

[121]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[122]  D. Wallach,et al.  Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. , 1995, Journal of inflammation.

[123]  S. Nagata,et al.  Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver , 1995, Nature Genetics.

[124]  S. Nagata,et al.  Fas and Fas ligand: lpr and gld mutations. , 1995, Immunology today.